Lamiaa M A Ali1, Sara A Shaker2, Rafael Pinol3, Angel Millan4, Mervat Y Hanafy2, Madiha H Helmy2, Maher A Kamel5, Shimaa A Mahmoud2. 1. Department of Biochemistry, Medical Research Institute, University of Alexandria, Alexandria, Egypt.; Institut des Biomolécules Max Mousseron UMR 5247 CNRS, UM-Faculté de Pharmacie, 15 Avenue Charles Flahault, 34093 Montpellier cedex 05, France. Electronic address: lamiaa.ali@alexu.edu.eg. 2. Department of Biochemistry, Medical Research Institute, University of Alexandria, Alexandria, Egypt. 3. Instituto de Ciencia de Materiales de Aragon-CSIC, Universidad de Zaragoza, Spain. 4. Instituto de Ciencia de Materiales de Aragon-CSIC, Universidad de Zaragoza, Spain. Electronic address: amillan@unizar.es. 5. Department of Biochemistry, Medical Research Institute, University of Alexandria, Alexandria, Egypt.. Electronic address: maher.kamel@alexu.edu.eg.
Abstract
AIMS: Evaluation of the anti-diabetic effect of superparamagnetic iron oxide nanoparticles (SPIONs) on Type 2 diabetic rats and compared their effect to metformin treatment. MAIN METHODS: Diabetic rats were treated with different doses of nanoparticles one time per week for 4 weeks. Fasting blood glucose level was determined for studied groups during the experimental period (30 days). At the end of the experiment, oral glucose tolerance test was carried out, serum samples were collected for biochemical assays. Then animals were sacrificed to obtain tissues for assessment of glucose transporters, insulin receptors and insulin signaling proteins. KEY FINDING: SPIONs treatment normalized fasting blood glucose and lowering insulin level in diabetic rats compared to untreated diabetic rats. SPIONs significantly ameliorate the glucose sensing and the active components of insulin signaling pathway. The anti-diabetic effects of SPIONs may be mediated through its effect on (i) hepatic peroxisome proliferator-activated receptor gamma coactivator 1-alpha content, which induced by SPIONs treatment in a dose-dependent manner, (ii) adipocytokines as SPIONs treated diabetic rats showed significantly higher levels of adiponectin and lower retinol binding protein 4 compared to untreated diabetic rats, (iii) lipid profile as SPIONs treatment significantly corrected the lipid profile in a dose-dependent manner and to a similar extent as metformin or even better. SIGNIFICANCE: To our knowledge, this is the first study that explores the anti-diabetic effects of SPIONs on diabetic model.
AIMS: Evaluation of the anti-diabetic effect of superparamagnetic iron oxide nanoparticles (SPIONs) on Type 2 diabetic rats and compared their effect to metformin treatment. MAIN METHODS: Diabetic rats were treated with different doses of nanoparticles one time per week for 4 weeks. Fasting blood glucose level was determined for studied groups during the experimental period (30 days). At the end of the experiment, oral glucose tolerance test was carried out, serum samples were collected for biochemical assays. Then animals were sacrificed to obtain tissues for assessment of glucose transporters, insulin receptors and insulin signaling proteins. KEY FINDING: SPIONs treatment normalized fasting blood glucose and lowering insulin level in diabetic rats compared to untreated diabetic rats. SPIONs significantly ameliorate the glucose sensing and the active components of insulin signaling pathway. The anti-diabetic effects of SPIONs may be mediated through its effect on (i) hepatic peroxisome proliferator-activated receptor gamma coactivator 1-alpha content, which induced by SPIONs treatment in a dose-dependent manner, (ii) adipocytokines as SPIONs treated diabetic rats showed significantly higher levels of adiponectin and lower retinol binding protein 4 compared to untreated diabetic rats, (iii) lipid profile as SPIONs treatment significantly corrected the lipid profile in a dose-dependent manner and to a similar extent as metformin or even better. SIGNIFICANCE: To our knowledge, this is the first study that explores the anti-diabetic effects of SPIONs on diabetic model.
Authors: Ángela-Patricia Hernández; Ania Micaelo; Rafael Piñol; Marina L García-Vaquero; José J Aramayona; Julio J Criado; Emilio Rodriguez; José Ignacio Sánchez-Gallego; Alicia Landeira-Viñuela; Pablo Juanes-Velasco; Paula Díez; Rafael Góngora; Ricardo Jara-Acevedo; Alberto Orfao; Javier Miana-Mena; María Jesús Muñoz; Sergio Villanueva; Ángel Millán; Manuel Fuentes Journal: J Nanobiotechnology Date: 2022-07-20 Impact factor: 9.429